KFG Wealth Management LLC Sells 198 Shares of Amgen Inc. (NASDAQ:AMGN)

KFG Wealth Management LLC decreased its holdings in shares of Amgen Inc. (NASDAQ:AMGN) by 4.8% during the 4th quarter, Holdings Channel reports. The firm owned 3,962 shares of the medical research company’s stock after selling 198 shares during the quarter. KFG Wealth Management LLC’s holdings in Amgen were worth $1,141,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Moneta Group Investment Advisors LLC raised its stake in Amgen by 83,875.6% during the 4th quarter. Moneta Group Investment Advisors LLC now owns 7,541,011 shares of the medical research company’s stock worth $1,980,571,000 after buying an additional 7,532,031 shares during the period. Norges Bank purchased a new stake in shares of Amgen in the fourth quarter worth approximately $1,351,778,000. Price T Rowe Associates Inc. MD raised its stake in shares of Amgen by 158.0% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 2,950,013 shares of the medical research company’s stock worth $774,791,000 after purchasing an additional 1,806,456 shares during the last quarter. International Assets Investment Management LLC purchased a new stake in shares of Amgen in the fourth quarter worth approximately $4,589,900,000. Finally, Morgan Stanley raised its stake in shares of Amgen by 12.9% in the fourth quarter. Morgan Stanley now owns 13,301,365 shares of the medical research company’s stock worth $3,493,471,000 after purchasing an additional 1,523,665 shares during the last quarter. Institutional investors own 76.50% of the company’s stock.

Analysts Set New Price Targets

A number of brokerages recently commented on AMGN. TD Cowen decreased their price target on Amgen from $370.00 to $360.00 and set a “buy” rating for the company in a research report on Wednesday. Morgan Stanley decreased their price target on Amgen from $281.00 to $278.00 and set an “equal weight” rating for the company in a research report on Wednesday, February 7th. Oppenheimer reaffirmed an “outperform” rating and set a $350.00 price target on shares of Amgen in a research report on Thursday, February 1st. The Goldman Sachs Group increased their price target on Amgen from $313.00 to $350.00 and gave the company a “buy” rating in a research report on Wednesday, February 7th. Finally, Daiwa Capital Markets raised Amgen from a “neutral” rating to a “buy” rating and increased their price target for the company from $264.00 to $320.00 in a research report on Thursday, December 21st. Ten analysts have rated the stock with a hold rating and ten have given a buy rating to the company’s stock. Based on data from MarketBeat, Amgen has a consensus rating of “Moderate Buy” and an average target price of $296.95.

Amgen Stock Performance

Shares of Amgen stock traded up $6.18 during trading hours on Friday, reaching $268.93. The company had a trading volume of 3,379,993 shares, compared to its average volume of 2,858,917. Amgen Inc. has a one year low of $211.71 and a one year high of $329.72. The business has a fifty day simple moving average of $277.34 and a 200 day simple moving average of $281.24. The company has a debt-to-equity ratio of 10.14, a current ratio of 1.65 and a quick ratio of 1.13. The firm has a market cap of $144.12 billion, a PE ratio of 21.22, a price-to-earnings-growth ratio of 2.46 and a beta of 0.58.

Amgen (NASDAQ:AMGN) last posted its quarterly earnings results on Tuesday, February 6th. The medical research company reported $4.71 EPS for the quarter, topping analysts’ consensus estimates of $4.66 by $0.05. Amgen had a return on equity of 154.27% and a net margin of 23.83%. The firm had revenue of $8.20 billion during the quarter, compared to analyst estimates of $8.13 billion. During the same period last year, the company earned $4.09 earnings per share. The business’s revenue for the quarter was up 19.8% on a year-over-year basis. On average, analysts anticipate that Amgen Inc. will post 19.45 earnings per share for the current fiscal year.

Amgen Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, June 7th. Investors of record on Friday, May 17th will be paid a dividend of $2.25 per share. This represents a $9.00 annualized dividend and a yield of 3.35%. The ex-dividend date of this dividend is Thursday, May 16th. Amgen’s dividend payout ratio is 72.06%.

Amgen Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.